Written Question·Department of Health and Social Care·UIN HL1760

Breast Cancer: Drugs

Tabled: 7 July 2026

Answered: 16 July 2026

Question

To ask His Majesty's Government what assessment they have made of the timeline for Enhertu medication for the treatment of patients with HER2-low metastatic breast cancer to be made available on the NHS.

Answer

HER2‑low breast cancer is managed with treatments for HER2‑negative breast cancer. The National Institute for Health and Care Excellence (NICE) has published guidance recommending a number of medicines for the treatment of HER2-negative breast cancer whic...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN HL1760) →